Hydroxynorketamine
| The four possible stereoisomers of Hydroxynorketamine | |||
| Clinical data | |||
|---|---|---|---|
| Other names | HNK; 6-Hydroxynorketamine; 6-HNK | ||
| ATC code | 
 | ||
| Identifiers | |||
| 
 | |||
| CAS Number | |||
| PubChem CID | |||
| ChemSpider | |||
| UNII | |||
| CompTox Dashboard (EPA) | |||
| Chemical and physical data | |||
| Formula | C12H14ClNO2 | ||
| Molar mass | 239.70 g·mol−1 | ||
| 3D model (JSmol) | |||
| 
 | |||
| 
 | |||
Hydroxynorketamine (HNK), or 6-hydroxynorketamine, is a minor metabolite of the anesthetic, dissociative, and antidepressant drug ketamine. It is formed by hydroxylation of the intermediate norketamine, another metabolite of ketamine. As of late 2019, (2R,6R)-HNK is in clinical trials for the treatment of depression.
The major metabolite of ketamine is norketamine (80%). Norketamine is secondarily converted into 4-, 5-, and 6-hydroxynorketamines (15%), mainly HNK (6-hydroxynorketamine). Ketamine is also transformed into hydroxyketamine (5%). As such, bioactivated HNK comprises less than 15% of a dose of ketamine.